BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shinoda S, Kaino S, Amano S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Deferasirox, an oral iron chelator, with gemcitabine synergistically inhibits pancreatic cancer cell growth in vitro and in vivo. Oncotarget 2018;9:28434-44. [PMID: 29983871 DOI: 10.18632/oncotarget.25421] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jomen W, Ohtake T, Akita T, Suto D, Yagi H, Osawa Y, Kohgo Y. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths. Biomed Pharmacother 2022;153:113363. [PMID: 35834989 DOI: 10.1016/j.biopha.2022.113363] [Reference Citation Analysis]
2 Gupta P, Pérez-Mancera PA, Kocher H, Nisbet A, Schettino G, Velliou EG. A Novel Scaffold-Based Hybrid Multicellular Model for Pancreatic Ductal Adenocarcinoma-Toward a Better Mimicry of the in vivo Tumor Microenvironment. Front Bioeng Biotechnol 2020;8:290. [PMID: 32391339 DOI: 10.3389/fbioe.2020.00290] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
3 Zhou N, Cui Y, Zhu R, Kuang Y, Ma W, Hou J, Zhu Y, Chen S, Xu X, Tan K, Cao P, Duan X, Fan Y. Deferasirox shows inhibition activity against cervical cancer in vitro and in vivo. Gynecologic Oncology 2022. [DOI: 10.1016/j.ygyno.2022.05.006] [Reference Citation Analysis]
4 Tian N, Zhou L, Yang D, Wu H, Ma Y, Lü L, Wu S. [Silencing RRM1 gene reverses paclitaxel resistance in human breast cancer cell line MCF- 7/R by inducing cell apoptosis]. Nan Fang Yi Ke Da Xue Xue Bao 2019;39:304-12. [PMID: 31068300 DOI: 10.12122/j.issn.1673-4254.2019.03.08] [Reference Citation Analysis]
5 Wang Y, Yu L, Ding J, Chen Y. Iron Metabolism in Cancer. Int J Mol Sci. 2018;20:pii: E95. [PMID: 30591630 DOI: 10.3390/ijms20010095] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 15.5] [Reference Citation Analysis]
6 Ding F, Zhang L, Chen H, Song H, Chen S, Xiao H. Enhancing the chemotherapeutic efficacy of platinum prodrug nanoparticles and inhibiting cancer metastasis by targeting iron homeostasis. Nanoscale Horiz 2020;5:999-1015. [PMID: 32364553 DOI: 10.1039/d0nh00148a] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
7 Park JM, Mau CZ, Chen YC, Su YH, Chen HA, Huang SY, Chang JS, Chiu CF. A case-control study in Taiwanese cohort and meta-analysis of serum ferritin in pancreatic cancer. Sci Rep 2021;11:21242. [PMID: 34711879 DOI: 10.1038/s41598-021-00650-7] [Reference Citation Analysis]
8 Zhan Y, Jiang L, Jin X, Ying S, Wu Z, Wang L, Yu W, Tong J, Zhang L, Lou Y, Qiu Y. Inhibiting RRM2 to enhance the anticancer activity of chemotherapy. Biomed Pharmacother 2021;133:110996. [PMID: 33227712 DOI: 10.1016/j.biopha.2020.110996] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Amano S, Kaino S, Shinoda S, Harima H, Matsumoto T, Fujisawa K, Takami T, Yamamoto N, Yamasaki T, Sakaida I. Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox. BMC Cancer 2020;20:681. [PMID: 32698792 DOI: 10.1186/s12885-020-07167-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
10 Özbolat G, Alizadeh Yegani A. Synthesis, characterization, biological activity and electrochemistry studies of iron(III) complex with curcumin-oxime ligand. Clin Exp Pharmacol Physiol 2020;47:1834-42. [PMID: 32497256 DOI: 10.1111/1440-1681.13359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Guo Q, Li L, Hou S, Yuan Z, Li C, Zhang W, Zheng L, Li X. The Role of Iron in Cancer Progression. Front Oncol 2021;11:778492. [PMID: 34858857 DOI: 10.3389/fonc.2021.778492] [Reference Citation Analysis]
12 Cheng G, Zielonka J, Hardy M, Ouari O, Chitambar CR, Dwinell MB, Kalyanaraman B. Synergistic inhibition of tumor cell proliferation by metformin and mito-metformin in the presence of iron chelators. Oncotarget 2019;10:3518-32. [PMID: 31191823 DOI: 10.18632/oncotarget.26943] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
13 Zhao Y, Zheng Y, Zhu Y, Zhang Y, Zhu H, Liu T. M1 Macrophage-Derived Exosomes Loaded with Gemcitabine and Deferasirox against Chemoresistant Pancreatic Cancer. Pharmaceutics 2021;13:1493. [PMID: 34575569 DOI: 10.3390/pharmaceutics13091493] [Reference Citation Analysis]
14 Abedi M, Rahgozar S. Puzzling Out Iron Complications in Cancer Drug Resistance. Crit Rev Oncol Hematol 2022;:103772. [PMID: 35914667 DOI: 10.1016/j.critrevonc.2022.103772] [Reference Citation Analysis]
15 Ibrahim O, O'Sullivan J. Iron chelators in cancer therapy. Biometals 2020;33:201-15. [PMID: 32757166 DOI: 10.1007/s10534-020-00243-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Lelièvre P, Sancey L, Coll JL, Deniaud A, Busser B. Iron Dysregulation in Human Cancer: Altered Metabolism, Biomarkers for Diagnosis, Prognosis, Monitoring and Rationale for Therapy. Cancers (Basel) 2020;12:E3524. [PMID: 33255972 DOI: 10.3390/cancers12123524] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
17 Xu Y, Wang Y, An J, Sedgwick AC, Li M, Xie J, Hu W, Kang J, Sen S, Steinbrueck A, Zhang B, Qiao L, Wageh S, Arambula JF, Liu L, Zhang H, Sessler JL, Kim JS. 2D-ultrathin MXene/DOXjade platform for iron chelation chemo-photothermal therapy. Bioactive Materials 2022;14:76-85. [DOI: 10.1016/j.bioactmat.2021.12.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
18 Greene CJ, Sharma NJ, Fiorica PN, Forrester E, Smith GJ, Gross KW, Kauffman EC. Suppressive effects of iron chelation in clear cell renal cell carcinoma and their dependency on VHL inactivation. Free Radical Biology and Medicine 2019;133:295-309. [DOI: 10.1016/j.freeradbiomed.2018.12.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
19 Qin J, Zhou C, Zhu M, Shi S, Zhang L, Zhao Y, Li C, Wang Y, Wang Y. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma. Photodiagnosis and Photodynamic Therapy 2020;31:101907. [DOI: 10.1016/j.pdpdt.2020.101907] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]